跳至主要内容
临床试验/NL-OMON51480
NL-OMON51480已完成3 期

DIRECT-2: Fasting mimicking Diet Program to ImpRovE ChemoTherapy in HR+, HER2- breast cancer - DIRECT-2

eids Universitair Medisch Centrum0 个研究点目标入组 240 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Clinical stage II-III, hormone receptor positive, HER2 negative breast cancer
  • Detectable and measurable disease (breast and/or lymph nodes)
  • Age >=18 years old
  • WHO performance status 0-2
  • Ability to read and understand Dutch language, accessibility to a computer
  • with internet connection and independent use of computer

排除标准

  • Patient history of invasive breast cancer or ipsilateral non-invasive breast
  • Active malignancy in the last 5 years, with the exclusion of basal cell
  • carcinoma or pre-invasive cervical neoplasia/dysplasia.
  • Body mass index (BMI) < 18.5 kg/m2
  • Pregnancy or lactating
  • Food allergy for ingredients of FMD (nuts, soy, honey)
  • A metabolic condition affecting gluconeogenesis or adaptation to periodic
  • fasting. (Diabetes Mellitus for example)

研究者

相似试验